Bartlett & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bartlett & Co’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,000	Closed	-$37K	–	720
2016 Q2	$37K	Hold	1,000	–	–	﹤0.01%	470
2016 Q1	$38K	Hold	1,000	–	–	﹤0.01%	450
2015 Q4	$51K	Hold	1,000	–	–	﹤0.01%	421
2015 Q3	$46K	Hold	1,000	–	–	﹤0.01%	424
2015 Q2	$58K	Hold	1,000	–	–	﹤0.01%	412
2015 Q1	$55K	Hold	1,000	–	–	﹤0.01%	422
2014 Q4	$50K	Hold	1,000	–	–	﹤0.01%	434
2014 Q3	$46K	Hold	1,000	–	–	﹤0.01%	441
2014 Q2	$44K	Hold	1,000	–	–	﹤0.01%	458
2014 Q1	$42K	Hold	1,000	–	–	﹤0.01%	448
2013 Q4	$37K	Hold	1,000	–	–	﹤0.01%	438
2013 Q3	$35K	Hold	1,000	–	–	﹤0.01%	448
2013 Q2	$29K	Buy	+1,000	New	+$28.4K	﹤0.01%	471

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Bartlett & Co's PBE Position: Q3 2016 in Review

Bartlett & Co sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2016, closing a stake of 1,000 shares — an estimated $37K sold.

Bartlett & Co first reported a position in PBE in Q2 2013 and held it in 13 quarters. The position peaked at $58K in Q2 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q3 2016.

Bartlett & Co reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2016 after selling out during the quarter.
Bartlett & Co sold 1,000 Invesco Biotechnology & Genome ETF shares in Q3 2016, an estimated $37K.
Bartlett & Co first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and held it in 13 quarters.
Bartlett & Co's Invesco Biotechnology & Genome ETF position peaked at $58K in Q2 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2016.

Based on Bartlett & Co's 13F filing for Q3 2016, filed 24 Oct 2016.